Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 2 L ESCC
  • 1 L GC/GEJC
  • 1L NSQ NSCLC
  • 1L SQ NSCLC
  • 2L NSCLC

This site is inteded for health care proffesional.

Improved mPFS, ORR and mDoR in patients with Non-squamous NSCLC and PD-L1 scores ≥1%1

Key Efficacy Outcome: mPFS

Etapidi with chemotherapy significantly prolonged median progression free survival by 29%

PFS benefits with Etapidi plus chemotherapy were consistent across most patient subgroups.

Independent review committee-assessed progression-free survival by prespecified subgroup in the ITT population

Key Efficacy Outcome: ORR & mDOR

Greater ORR and longer DoR with Etapidi plus chemotherapy versus chemotherapy alone

View safety in Non-squamous NSCLC

Independent review committee-assessed progression-free survival in the ITT population (final analysis data cut-off : 26 October 2020). CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; PD L1, programmed death-ligand 1; PFS, progression-free survival; DoR=duration of response, IRC=independent review committee, ITT=intent-to-treat, mDoR=median duration of response, ORR=objective response rate, PPC=pemetrexed and platinum-based chemotherapy, PR=partial response.

Reference: 1. Lu S, et al. J Thorac Oncol. 2021;16(9):1512-1522. 2. Lu S et al., ESMO OPEN 2024 volume 9, issue 10, https://doi.org/10.1016/j.esmoop.2024.103728